Articles
-
Medicare’s ‘Coverage With Evidence Development’: A Barrier to Patient Access and Innovation
CMS should abandon CED or, at minimum, reform and restrict its use only for off-label applications of therapies.
Categorized in -
Alternatives to the QALY for Comparative Effectiveness Research
We now have useful and valid alternatives that allow for the assessment and valuation of treatments that improve population health without discriminating against vulnerable patient populations.
Categorized in -
Medicare Coverage of Weight Loss Drugs Could Significantly Reduce Costs
USC Schaeffer white paper finds that increasing access to obesity treatments would help save lives and reduce healthcare costs.
Categorized in -
Comments to CMS on the Inflation Reduction Act’s Drug Price Negotiation Program
Over 20 researchers cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations for the Medicare Drug Price Negotiation Program
Categorized in -
New Schaeffer White Paper Offers Solutions to Ensure Greater Patient Access to Prescription Drugs
The researchers propose three strategies for mitigating negative impacts of the Inflation Reduction Act to ensure greater patient access, increased innovation and lower costs.
Categorized in -
Senate Finance Committee Explores Costly, Secretive Practices in the Drug Supply Chain
Karen Van Nuys testified at the hearing, calling transparency “an essential first step.”
-
Ending Health Insurance for Generic Drugs Would Save Patients Money
Eliminating insurance for generics might make patients nervous at first, but the payoff would be stable and affordable prices.
Categorized in -
Prominent Health Executive Tom Priselac Named Vice Chair of Schaeffer Center Advisory Board
Priselac, who is CEO and president of Cedars-Sinai, has served on the board since its inception in 2011.
-
Should the Government Restrict Direct-to-Consumer Prescription Drug Advertising? Six Takeaways on Their Effects.Â
Policymakers should proceed with caution as they design proposals to restrict advertising. Â
Categorized in
